{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:49:22Z","timestamp":1740160162699,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s13300-017-0225-z","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T06:06:11Z","timestamp":1484287571000},"page":"189-195","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data"],"prefix":"10.1007","volume":"8","author":[{"given":"Kohei","family":"Kaku","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael Lyng","family":"Wolden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Hyllested-Winge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emil","family":"N\u00f8rtoft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"key":"225_CR1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1046\/j.1365-2125.2003.01953.x","volume":"57","author":"K Martin","year":"2004","unstructured":"Martin K, B\u00e9gaud B, Latry P, Miremont-Salam\u00e9 G, Fourrier A, Moore N. Differences between clinical trials and postmarketing use. Br J Clin Pharmacol. 2004;57:86\u201392.","journal-title":"Br J Clin Pharmacol"},{"key":"225_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.279.3.222","volume":"279","author":"A Pablos-M\u00e9ndez","year":"1998","unstructured":"Pablos-M\u00e9ndez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA. 1998;279:222\u20135.","journal-title":"JAMA"},{"key":"225_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s13300-014-0076-9","volume":"5","author":"J Vora","year":"2014","unstructured":"Vora J, Christensen T, Rana A, Bain SC. Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials. Diabetes Ther. 2014;5:435\u201346.","journal-title":"Diabetes Ther"},{"key":"225_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/dom.12032","volume":"15","author":"RE Ratner","year":"2013","unstructured":"Ratner RE, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175\u201384.","journal-title":"Diabetes Obes Metab"},{"key":"225_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/j.2040-1124.2012.00240.x","volume":"4","author":"Y Iwamoto","year":"2013","unstructured":"Iwamoto Y, Clauson P, Nishida T, Kaku K. Insulin degludec in Japanese patients with type 1 diabetes mellitus: a randomized controlled trial. J Diabetes Investig. 2013;4:62\u20138.","journal-title":"J Diabetes Investig"},{"key":"225_CR6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/dme.12086","volume":"30","author":"N Freemantle","year":"2013","unstructured":"Freemantle N, Meneghini L, Christensen T, Wolden ML, Jendle J, Ratner R. Insulin degludec improves health-related quality of life (SF-36\u00ae) compared with insulin glargine in people with Type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials. Diabet Med. 2013;30:226\u201332.","journal-title":"Diabet Med"},{"key":"225_CR7","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1007\/s00125-015-3648-y","volume":"58","author":"T Nakamura","year":"2015","unstructured":"Nakamura T, Sakaguchi K, So A, et al. Effects of insulin degludec and insulin glargine on day-to-day fasting plasma glucose variability in individuals with type 1 diabetes: a multicentre, randomised, crossover study. Diabetologia. 2015;58:2013\u20139.","journal-title":"Diabetologia"},{"key":"225_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40780-015-0027-2","volume":"1","author":"M Okada","year":"2015","unstructured":"Okada M, Okada M, Nishigami J, et al. Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus. J Pharm Health Care Sci. 2015;1:26.","journal-title":"J Pharm Health Care Sci"},{"key":"225_CR9","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/dme.13002","volume":"33","author":"S Heller","year":"2016","unstructured":"Heller S, Mathieu C, Kapur R, Wolden ML, Zinman B. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia. Diabet Med. 2016;33:478\u201387.","journal-title":"Diabet Med"},{"key":"225_CR10","unstructured":"European Agency for Evaluation of Medicinal Products (EMA). Committee for Proprietary Medicinal Products. EMEA\/CPMP\/EWP\/1080\/00Rev.1: Guideline on clinical investigation of medicinal products in the treatment of diabetes mellitus. 2010. \n                    www.emea.europa.eu\n                    \n                  . Accessed Sept 2016."},{"key":"225_CR11","unstructured":"U.S. Federal Drug Administration. Guidance for industry. Diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention\u2014draft guidance. February 2008. \n                    www.fda.gov\n                    \n                  . Accessed Sept 2016."},{"key":"225_CR12","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.2337\/dc12-1205","volume":"35","author":"B Zinman","year":"2012","unstructured":"Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with Type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464\u201371.","journal-title":"Diabetes Care"},{"key":"225_CR13","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1111\/dme.12303","volume":"30","author":"HW Rodbard","year":"2013","unstructured":"Rodbard HW, Cariou B, Zinman B, et al. Comparison of insulin degludec with insulin glargine in insulin-naive subjects with Type 2 diabetes: a 2-year randomized, treat-to-target trial. Diabet Med. 2013;30:1298\u2013304.","journal-title":"Diabet Med"},{"key":"225_CR14","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","volume":"379","author":"AJ Garber","year":"2012","unstructured":"Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-long-acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1498\u2013507.","journal-title":"Lancet"},{"key":"225_CR15","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/S0140-6736(12)60204-9","volume":"379","author":"S Heller","year":"2012","unstructured":"Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultralongacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN Basal-Bolus Type 1): a Phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489\u201397.","journal-title":"Lancet"},{"key":"225_CR16","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1111\/dme.12243","volume":"30","author":"BW Bode","year":"2013","unstructured":"Bode BW, Buse JB, Fisher M, et al. Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN(\u00ae) Basal-Bolus Type 1): 2-year results of a randomized clinical trial. Diabet Med. 2013;30:1293\u20137.","journal-title":"Diabet Med"},{"key":"225_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.2337\/dc12-1668","volume":"36","author":"L Meneghini","year":"2013","unstructured":"Meneghini L, Atkin SL, Gough SC, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with Type 2 diabetes. Diabetes Care. 2013;36:858\u201364.","journal-title":"Diabetes Care"},{"key":"225_CR18","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1210\/jc.2012-3249","volume":"98","author":"C Mathieu","year":"2013","unstructured":"Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with Type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98:1154\u201362.","journal-title":"J Clin Endocrinol Metab"},{"key":"225_CR19","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/jdi.12102","volume":"4","author":"Y Onishi","year":"2013","unstructured":"Onishi Y, Iwamoto Y, Yoo SJ, Clauson P, Tamer SC, Park S. Insulin degludec compared with insulin glargine in insulin na\u00efve patients with Type 2 diabetes: a 26-week, randomized, controlled, Pan-Asian, treat-to-target trial. J Diabetes Investig. 2013;4:605\u201312.","journal-title":"J Diabetes Investig"},{"key":"225_CR20","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.2337\/dc12-2329","volume":"36","author":"SC Gough","year":"2013","unstructured":"Gough SC, Bhargava A, Jain R, Mersebach H, Rasmussen S, Bergenstal RM. Low-volume insulin degludec 200 units\/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-na\u00efve patients with Type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care. 2013;36:2536\u201342.","journal-title":"Diabetes Care"},{"key":"225_CR21","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.2169\/internalmedicine.54.3993","volume":"54","author":"I Kanazawa","year":"2015","unstructured":"Kanazawa I, Notsu M, Tanaka K, Kiyohara N, Tada Y, Sugimoto T. An open-label longitudinal study on the efficacy of switching from insulin glargine or detemir to degludec in type 2 diabetes mellitus. Intern Med. 2015;54:1591\u20138.","journal-title":"Intern Med"},{"key":"225_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s13300-013-0048-5","volume":"4","author":"Y Kusunoki","year":"2013","unstructured":"Kusunoki Y, Katsuno T, Miyakoshi K, et al. Effects of switching from insulin glargine or detemir to insulin degludec in patients with type 1 diabetes mellitus. Diabetes Ther. 2013;4:461\u201372.","journal-title":"Diabetes Ther"},{"key":"225_CR23","doi-asserted-by":"publisher","first-page":"176261","DOI":"10.1155\/2015\/176261","volume":"2015","author":"Y Tosaka","year":"2015","unstructured":"Tosaka Y, Kanazawa A, Ikeda F, et al. Switching from twice-daily basal insulin injections to once-daily insulin degludec injection for basal-bolus insulin regimen in japanese patients with type 1 diabetes: a pilot study. Int J Endocrinol. 2015;2015:176261.","journal-title":"Int J Endocrinol"},{"key":"225_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1507\/endocrj.EJ15-0245","volume":"63","author":"T Urakami","year":"2016","unstructured":"Urakami T, Kuwabara R, Aoki M, Okuno M, Suzuki J. Efficacy and safety of switching from insulin glargine to insulin degludec in young people with type 1 diabetes. Endocr J. 2016;63:159\u201367.","journal-title":"Endocr J"},{"key":"225_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3111\/13696998.2014.975234","volume":"18","author":"M Evans","year":"2015","unstructured":"Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice\u2014a case-based evaluation. J Med Econ. 2015;18:96\u2013105.","journal-title":"J Med Econ."},{"key":"225_CR26","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1185\/03007995.2015.1058252","volume":"31","author":"L Landstedt-Hallin","year":"2015","unstructured":"Landstedt-Hallin L. Changes in HbA1c, insulin dose and incidence of hypoglycemia in patients with type 1 diabetes after switching to insulin degludec in an outpatient setting: an observational study. Curr Med Res Opin. 2015;31:1487\u201393.","journal-title":"Curr Med Res Opin"},{"key":"225_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/jdi.12399","volume":"7","author":"I Ikushima","year":"2016","unstructured":"Ikushima I, Kaku K, Hirao K, Bardtrum L, Haahr H. Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients. J Diabetes Investig. 2016;7:270\u20135.","journal-title":"J Diabetes Investig"},{"key":"225_CR28","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1177\/1932296814564396","volume":"9","author":"M Komuro","year":"2015","unstructured":"Komuro M, Inoue G, Tabata M, et al. Insulin degludec requires lower bolus insulin doses than does insulin glargine in Japanese diabetic patients with insulin-dependent state. J Diabetes Sci Technol. 2015;9:632\u20138.","journal-title":"J Diabetes Sci Technol."},{"key":"225_CR29","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40268-014-0048-6","volume":"14","author":"R Nakae","year":"2014","unstructured":"Nakae R, Kusunoki Y, Katsuno T, et al. Medium-term effects of insulin degludec on patients with type 1 diabetes mellitus. Drugs R D. 2014;14:133\u20138.","journal-title":"Drugs R D"},{"key":"225_CR30","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1463-1326.2012.01627.x","volume":"14","author":"T Heise","year":"2012","unstructured":"Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14:859\u201364.","journal-title":"Diabetes Obes Metab"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-017-0225-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13300-017-0225-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-017-0225-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T15:35:46Z","timestamp":1548084946000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13300-017-0225-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["225"],"URL":"https:\/\/doi.org\/10.1007\/s13300-017-0225-z","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"type":"print","value":"1869-6953"},{"type":"electronic","value":"1869-6961"}],"subject":[],"published":{"date-parts":[[2017,1,13]]},"assertion":[{"value":"3 November 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2017","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}